These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6401998)

  • 1. Human blood platelet behaviour after inhibition of thromboxane synthetase.
    Heptinstall S; Fox SC
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):31S-37S. PubMed ID: 6401998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dazoxiben and low-dose aspirin on platelet behaviour in man.
    Jones EW; Cockbill SR; Cowley AJ; Hanley SP; Heptinstall S
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):39S-44S. PubMed ID: 6401999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
    Sills T; Heptinstall S
    Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T; Joussemet M; Hainaut J
    Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboxane synthetase inhibitors differentially antagonize thromboxane receptors in vascular smooth muscle.
    Smith EF; Lefer AM; Smith JB; Nicolaou KC
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(2):130-4. PubMed ID: 6276789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
    Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
    Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
    Patscheke H
    Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of heparin on platelet aggregation and release and thromboxane A2 production.
    Mohammad SF; Anderson WH; Smith JB; Chuang HY; Mason RG
    Am J Pathol; 1981 Aug; 104(2):132-41. PubMed ID: 7258300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour.
    Heptinstall S; Bevan J; Cockbill SR; Hanley SP; Parry MJ
    Thromb Res; 1980 Oct; 20(2):219-30. PubMed ID: 7193919
    [No Abstract]   [Full Text] [Related]  

  • 11. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death.
    Lefer AM; Okamatsu S; Smith EF; Smith JB
    Thromb Res; 1981 Aug; 23(3):265-73. PubMed ID: 6795758
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
    Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
    Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet thromboxane synthetase by L-1-tosylamido-2-phenylethyl chloromethyl ketone.
    Yahn DM; Feinstein MB
    Prostaglandins; 1981 Feb; 21(2):243-54. PubMed ID: 7194491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of UK-38485 (dazmegrel), a specific inhibitor of thromboxane A2 synthetase.
    Rebec MV; Skrinska VA
    Prostaglandins Leukot Essent Fatty Acids; 1989 Dec; 38(3):207-12. PubMed ID: 2622975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase.
    Takami M; Tsukada W
    Pharmacol Res; 1998 Aug; 38(2):133-9. PubMed ID: 9721601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dazoxiben on platelet-vessel wall interaction.
    Davies JA; Menys VC
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):45S-46S. PubMed ID: 6681703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.